Dapagliflozin临床降低因心衰住院/心血管死亡风险，但MACE降低无显著性差异

These positive results are clinically relevant to the 425 million people worldwide living with diabetes, of whom those with type 2 diabetes have a two-to-five times greater risk of heart failure along with an increased risk of a heart attack or stroke. Heart failure survival rates are only 50% after five years from diagnosis, which is why these new findings are so important in broadening our understanding of how to go beyond blood glucose so we may better address this serious and often overlooked cardiovascular complication.

——Elisabeth Björk

Vice President, Head of Cardiovascular, Renal and Metabolism, Global Medicines Development